Incorporated in Shanghai International Medical Zone in 2012, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“Endovastec™”) is one of the first companies listed on the STAR Market (stock code: 688016.SH) in 2019. It has been granted the titles of National New and High-tech Enterprise, one of the first Chinese Specialized and Sophisticated “Little Giant” Enterprises that Produce Novel and Unique Products, National Enterprise Technology Center, Multinational R&D Center, national-level “Green Factory”, Shanghai Municipal Sci-tech “Little Giant” Enterprise, Shanghai Municipal Enterprise Technology Center, and AAA Credit-Rating Enterprise, as well as honors such as the National Intellectual Property Advantage Enterprise, Shanghai Municipal Quality Management Award, Shanghai Municipal Quality Benchmark, and Shanghai Brand.

Endovastec™ focuses on the research and development (R&D), manufacturing, sales and services of aortic and peripheral vascular intervention devices. It has four subsidiaries, namely Bluevastec™, VasoLutions™,Intervastec™ and Endovastec US™, which are committed to the R&D and sales of intervention medical devices for peripheral venous diseases, peripheral arterial diseases and tumors, respectively. The company has launched 13 products on the market, mainly including thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, drug-coated balloon dilatation catheters, peripheral vascular stents and balloon dilatation catheters. Among them, five have obtained CE marking. As of September 2023, the products of Endovastec™ have been available in over 2,000 hospitals across China and reached 29 countries and regions worldwide, saving more than 230,000 lives globally. In 2021, the domestic market share of our aortic endovascular intervention products has reached 29%, ranking first in China. At present, the company’s domestic operations cover 31 provinces, autonomous regions, and municipalities in China, while its international operations extend to Europe, Latin America, Southeast Asia and many other regions.

With technological innovation as its core driving force and upholding the innovation philosophy of “being the number one or the only one”, Endovastec™ is striving for development through rapid innovation. In recent years, the company’s annual investment in research and development has accounted for more than 15% of its annual revenue, increasing year by year. The R&D personnel comprise nearly 30% of the total company workforce, including a group of national and Shanghai-level top-notch scientific research professionals. As of September 2023, the company has obtained over 300 patents authorized domestically and internationally, including more than 160 invention patents. It has won the second prize of the Chinese National Science and Technology Progress Award, and has won the first prize of the Shanghai Municipal Science and Technology Progress Award twice. Among the products already launched and under development, eight have been approved by the National Medical Products Administration (NMPA) of China to go through the Special Review Procedures for Innovative Medical Devices (Green Path), outperforming most other companies in the industry. A collection of clinical academic articles on its key products has been published in internationally renowned medical journals.

The operation headquarters of Endovastec™ is located in Shanghai, with nearly 24,000 square meters of R&D, manufacturing and office space, more than 7,000 square meters of Class 10,000 clean rooms in line with the national standards for the production of Class III implantable products, and more than 900 employees. Advocating that “the patient always comes first” and adhering to the mission of providing trustworthy and universal access to state-of-the-art total solutions to vascular circulatory diseases, Endovastec™ is committed to building a globally leading group of people centric enterprises of emerging medical technologies through technological innovation.